Figure 1



Figure 2

```
PEP1                IPVLDENGLFAP
PEP2                 WGLDYERGNYEE
PEP3               DALAVDQMGRFG
PEP4                  VLVGEKGLFEGG
PEP5               EALVLDTNGLMS
PEP6                    ADRTQGLGWGAS
PEP7               EEVGSILYGLGG
CONSENSUS               DE-GLF
```

Figure 3


PEP1
19.81 (45%)
PEP7
14.86 (48%)
PEP3
8.35 (34%)
PEP4
8.82 (33%)
PEP2
12.63 (36%)
PEP6
10.00 (33%)
PEP5
11.44 (35%)
CONTROL
4.91 (4%)

Figure 4


80
60
40
20
0
% Inhibition
PEP1
PEP7
PEP3
PEP4
PEP2
PEP6
PEP5
Control
E. coli clones

Figure 5


100
50
0
-50
-100
% inhibition
0.1
0.5
1
Concentration of peptide (mg/ml)
LOS
(Concentration o.1, 0.5, and 1.0 mg/ml)
PEP 1
(CGPIPVLDENGLFAPGPC)
Control peptide
(*CKSNPIHIIKNRRNIPC*)

Figure 6


OD 410nm
2
1.5
1
0.5
0
0
100
200
300
400
MAb 2C7 concentration (ng/ml)
Octa-MAP 1
(CGPIPVLDENGLEAPGPC)
Octa-MAP control
(CGPEARDEGTITLERGPC)

Figure 7



Tetra-MAP1
(CGPIPVLDENGLFAPGPC)

Octa-MAP1

PEP1

Tetra-MAP (Control)
(CGPEARDEGTITLERGPC)

Octa-MAP (Control)

Purified LOS

Figure 8

A. OCTA-MAP1



B. LOS (positive control)



C. FREUND'S ADJUVANT (negative control)



D. octa-MAP CONTROL (unrelated peptide, [negative control])



⇧ =boost

DOCKET NO.

Figure 9



002207 "226960

Figure 10



* $p < 0.001$; comparing response to Octa-MAP1 vs negative controls

002207 "1226960

Figure 11



Figure 12


Strain 15253
Strain 15253 lgtG
% survival
250
200
150
100
50
0
A. mAb 2C7
B. Normal mouse serum
C. Post-octa-MAP1 (pooled serum, week 7-11, 1 mouse)
D. Post-LOS (pooled serum, week 7-11, 1 mouse)
E. Post-Adjuvant (pooled serum, week 7-11, 1 mouse)
F. Post-MAP control (pooled serum, week 7-11, 1 mouse)
Antibody source

002807 "a2266960

Figure 13